GlycoMimetics to Host Event on Phase 3 Uproleselan Results in R/R AML on June 4, 2024

GlycoMimetics, Inc. (Nasdaq: GLYC), a biotechnology firm in its advanced clinical stage, is at the forefront of developing glycobiology-based treatments for cancer and inflammatory diseases. The company recently announced a significant event: an opinion leader panel scheduled for Tuesday, June 4, 2024, at 8:30 am ET. This event aims to provide an extensive overview of GlycoMimetics' critical Phase 3 study data on uproleselan, targeting relapsed or refractory (R/R) acute myeloid leukemia (AML).

The panel will highlight the insights of Daniel DeAngelo, M.D., Ph.D., Professor of Medicine at Harvard Medical School and Chief of the Division of Leukemia at Dana-Farber Cancer Institute. Dr. DeAngelo will elucidate the results of the pivotal Phase 3 study on uproleselan, discuss the current treatment landscape for AML, and underscore the areas of unmet patient needs.

Interested individuals can access the event via phone by registering through the provided link to obtain dial-in details. Participants are advised to connect 15 minutes before the event starts. Additionally, a live webcast will be accessible on the "Investors" section of the GlycoMimetics website, with a replay available for 30 days post-event.

Understanding AML

Acute myeloid leukemia (AML) is the most prevalent acute leukemia in adults, affecting around 21,000 people annually in the United States. Despite various treatment approaches, the prognosis remains dire, necessitating new therapeutic strategies to enhance patient outcomes. Notably, AML has the lowest five-year survival rate among adult leukemias, standing at 31.7%, with the figure dropping to 10% for relapsed or refractory cases.

Uproleselan: A Promising Candidate

Uproleselan is an innovative, investigational E-selectin antagonist developed by GlycoMimetics. This first-in-class compound has garnered Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration (FDA) and a Breakthrough Therapy designation from the Chinese National Medical Products Administration, specifically for adult AML patients with relapsed or refractory disease.

In AML, E-selectin plays a critical role as a leukocyte adhesion molecule expressed on endothelial cells in the vasculature and bone marrow. The interaction between E-selectin and leukemic cells within the Bone Marrow microEnvironment (BME) facilitates the survival of these malignant cells, shielding them from standard therapies. Uproleselan aims to disrupt this interaction, thereby preventing leukemic cells from leveraging the protective BME niche.

About GlycoMimetics

GlycoMimetics is dedicated to pioneering glycobiology-based therapies for cancer, particularly AML, and various inflammatory diseases. The company's scientific strategy hinges on comprehending the role of carbohydrates in cell recognition. Their unique chemistry platform is designed to create small molecule drugs, known as glycomimetics, which modify carbohydrate-mediated recognition across a spectrum of diseases, including cancer and inflammation. Leveraging its scientific expertise, GlycoMimetics is advancing a pipeline of proprietary drug candidates, striving to develop transformative therapies for conditions with significant unmet medical needs. The company is headquartered in Rockville, Maryland, within the BioHealth Capital Region.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!